Arcutis Biotherapeutics, Inc. has announced the commencement of a Phase 2 open-label clinical study, INTEGUMENT-INFANT, to assess the safety and tolerability of the investigational drug ZORYVE (roflumilast) cream 0.05% in infants with atopic dermatitis. The study will involve infants aged 3 months to less than 24 months and will evaluate the effects of once-daily application of the cream over a four-week period. ZORYVE cream, a potent and selective phosphodiesterase-4 (PDE4) inhibitor, is being investigated for its potential to address the high prevalence and early onset of atopic dermatitis in children. Current treatment options for infants are limited, and this study aims to explore alternatives that could reduce or replace steroid use in this demographic. As of now, the results of the study have not been presented.